Natural Statins and Stroke | Zendy

Anthony S. Wierzbicki | Zendy; Martin Crook | Zendy; Dimitri P. Mikhailidis | Zendy; A F Winder | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Natural Statins and Stroke

Author(s) -

Anthony S. Wierzbicki,

Martin Crook,

Dimitri P. Mikhailidis,

A F Winder

Publication year - 2000

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.101.3.e45

Subject(s) - medicine , stroke (engine) , surrogate endpoint , ischaemic stroke , clinical endpoint , natural history , clinical trial , gerontology , ischemia , mechanical engineering , engineering

To the Editor: The comprehensive review by Furberg1 of natural statins and stroke raises a number of issues. Stroke was a secondary end point in these studies in patients with cardiovascular disease (CVD). Primary end-point trials in stroke are awaited. Surrogate markers can be valuable guides to the introduction of better therapies before large-scale trials are completed. LDL may be the best surrogate marker of prognosis in CVD. In stroke, the primary role of LDL is less clear, but the subgroup analyses and the association of LDL reduction with mechanisms of plaque stabilization imply the need for effective therapy. The new target of LDL <100 mg/dL (<2.5 mmol/L) may be difficult to achieve with some natural statins. The extent to which …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research